SMS Pharmaceuticals Limited announced that its Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prestigious prequalification approval from the World Health Organisation (WHO), Geneva.
This recognition marks a significant regulatory milestone for SMS Pharma, strengthening its global positioning, particularly in the Anti-Retroviral (ARV) API segment. The WHO prequalification endorses the company’s adherence to international standards for quality and safety, paving the way for wider participation in global health programs and increased market access.
Mr. P. Vamsi Krishna, Executive Director of SMS Pharmaceuticals, commented on the achievement:
“The WHO Geneva prequalification reflects the company’s strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness.”
In the meantime, SMS Pharmaceuticals opened today at ₹231.11, matching its intraday low, and surged to a high of ₹248.00. The stock remains well below its 52-week high of ₹398.00 but comfortably above its 52-week low of ₹175.25.
